ProMIS Neurosciences IPO év
Mi az ProMIS Neurosciences IPO év?
A IPO év az ProMIS Neurosciences, Inc. - 2007
Mi a IPO év meghatározása?
A kezdeti nyilvános ajánlattétel olyan nyilvános ajánlattétel, amelyben a társaság részvényeit általában olyan intézményi befektetőknek adják el, akik viszont értékpapírcserében először értékesítik a nagyközönségnek.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO év a Health Care szektor a TSX-on cégekben a ProMIS Neurosciences -hoz képest
Mit csinál ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
ipo év -hoz hasonló cégek ProMIS Neurosciences
- G3 Exploration nak IPO év 2006 van
- Evolis SA nak IPO év 2006 van
- Unity Infraprojects nak IPO év 2006 van
- News Invest nak IPO év 2006 van
- AuStar Gold nak IPO év 2006 van
- Sky and Space Global nak IPO év 2006 van
- ProMIS Neurosciences nak IPO év 2007 van
- Manas Resources nak IPO év 2008 van
- Mastech Digital Inc nak IPO év 2008 van
- MYR Inc nak IPO év 2008 van
- Dana Inc nak IPO év 2008 van
- American Water Works Co nak IPO év 2008 van
- Chromadex Corp nak IPO év 2008 van